Skip to content
Publicly Available Published by De Gruyter October 18, 2016

The prevalence and genotypes of alpha-thalassemia in Adıyaman: two rare alpha variants

Adıyaman’da alfa-talasemi genotipleri ve sıklığı: İki nadir alfa variant
Ahmet Genç EMAIL logo , Yusuf Sevgiler , Süleyman Bayram and Eyyüp Rencüzoğulları

Abstract

Introduction

Alpha-thalassemia (α-thal) is one of the most common diseases in the world, and is more common in the Mediterranean countries, the Middle East, Southeast Asia, and Africa. The aim of this study was to determine the prevalence and genotypes of α-thal in high school students in Adıyaman province, Southeast Turkey.

Methods

In this study, a total of 289 people were screened for α-thal mutations by multiplex gap-PCR and ARMS.

Results

α-thal mutation frequency was determined to be 13.15%. Five different mutations were identified and the most common mutation was found to be −3.7 deletions with a frequency of 11.07%. We identified two heterozygous alpha hemoglobin variants. We described the second case of heterozygote Hb Fontainebleau of Turkish origin. Here, we also reported another heterozygote hemoglobin variant, Hb Q-Iran, previously reported in a few cases in another part of Turkey.

Discussion and conclusion

This study covers the frequency of α-thal disease, and the molecular analysis is the first study in the Southeastern Anatolia Region of Turkey. The prevalence of the α-thal trait is low in Adıyaman Province, compared to the other cities of Turkey.

Özet

GİRİŞ ve AMAÇ

Alfa talasemi başta Akdeniz, Ortadoğu, Güneydoğu Asya ve Afrika ülkelerinde olmak üzere, dünyada en yaygın görülen hastalıklardan biridir. Bu çalışmanın amacı ülkemizin güneydoğusunda yer alan Adıyaman ilinde okuyan lise öğrencilerinde alfa talasemi sıklığını ve genotiplerini belirlemektir.

YÖNTEM ve GEREÇLER

Bu çalışmada, toplamda 289 kişinin alfa-talasemi mutasyonları multipleks gap-PCR ve ARMS yöntemi ile taranmıştır.

BULGULAR

Alfa-talasemi mutasyon sıklığı %13,15 olarak belirlenmiştir. Beş farklı mutasyon tanımlanmış ve en yaygın mutasyon −3.7 delesyonu %11,07 sıklıkta bulunmuştur. Ayrıca iki alfa hemoglobin varyantı heterozigot olarak tanımlanmıştır. Bu çalışmada tanımlanan Hb Fontainebleau ülkemizdeki ikinci vakadır. Diğer Hb varyantı heterozigot Hb Q-Iran olarak rapor edilmiş olup, bu varyant ülkemizin değişik illerinde önceden rapor edilmiştir.

TARTIŞMA ve SONUÇ

Ülkemiz Güneydoğu Anadolu Bölgesi’nde alfa-talasemi hastalığının sıklığını ve genotiplerinin belirlendiği ilk çalışma olmuştur. Alfa talasemi sıklığı ülkemizdeki diğer ilerle kıyaslandığında Adıyaman ilinde düşük bulunmuştur.

Introduction

Alpha-thalassemia (α-thal) is the most common recessively inherited globin disorder throughout the world and is characterized by deficient or absent synthesis of one or both functional α-globin genes located on the short arm of chromosome 16. It most frequently results from deletion of one (–α/αα) or both α-globin (–/αα) genes and, less frequently, from different non-deletional mutations [1]. It is more prevalent throughout the Mediterranean countries, the Middle East, Southeast Asia, and Africa [2]. The clinical severity of α-thalassemia varies depending on the number of affected α-globin genes [3]. The α-thal trait caused by the dysfunction or deletions of one or two α-globin genes commonly displays no symptoms or very mild anemia [4].

Distribution of mutations causing α-thal has been reported in various provinces in Turkey, and some studies have shown that the –α3.7/αα genotypes are the most common mutations in Turkish patients [5], [6], [7], [8]. No epidemiological study of α-thal and α-globin variants has been undertaken in Adıyaman province, in the Southeastern Anatolia Region of Turkey. Thus, the aim of the present investigation was to determine the α-globin variants and frequency of the α-thal mutations in the province of Adıyaman in high school students. Here, we describe the results of molecular analyses of 289 blood samples that had microcytosis and/or anemia. In this study, the frequency and genotypes of α-thal were determined. Also, we identified two rare α-globin variants.

Materials and methods

The study was approved by the Non-Invasive Research Ethics Committee of Firat University (date: 11.03.2014, number: 05/01). It involved 289 blood samples in Adıyaman Province. Screening tests and the collection of blood have been described in a previous study [9]. Students with low 2.5% HbA2 below 80 fL mean corpuscular volume (MCV); and considered possible carriers of α-thal were included in the study. As our financial support did not allow for determining plasma iron and ferritin levels, we only took microcytosis as a sign of iron deficiency.

In cases with possible α-thal, mutation screening was performed by the gap-PCR and ARMS [10], [11]. DNA sequencing was used to verify IVSI –5nt and polyA2 (AATAAA>AATGAA) mutations and also to characterize the abnormal α-variants [12].

Results

Of the 289 Adıyaman high school students, 38 (13.15%) were identified as carriers of α-thal. Molecular analysis of 38 samples revealed five different mutations [–α3.7, IVSI –5nt, –20.5, –α4.2and polyA2 (AATAAA>AATGAA)] and the most common mutation was 3.7 deletions with a frequency of 11.07%. The frequency of genotypes of α-thal mutations and hematological parameters is shown in Table 1.

Table 1:

The distribution of heterozygote α-thal mutations and allele frequencies in Turkey.

α-thalassemia mutationsnPresent study Adiyaman, %Istanbul % (n=95) (Karakaş et al. [13])Isparta % (n=8) (Gulen et al. [7])Hatay % (n=97) (Celik et al. [8])Adana % (n=225) (Guvenc et al. [6])
–α3.7α/αα3211.0723.1 (19)10.9 (5)57.73 (56)53.33 (120)
αIVSI −5ntα/αα31.046.3 (3)2.06 (2)
–(α)20.5/αα10.359.4 (13)4.3 (2)6.66 (15)
–α4.2/αα10.351.03 (1)0.44 (1)
αPolyA2α/αα10.350.52.2 (1)1.03 (1)4.0 (9)

n, patient number.

We observed two abnormal HPLC-elution patterns while screening high school students for thalassemia. Chromatographic analysis of red cell lysates revealed that one of these variants comprised 18.0% of the total Hb. An abnormal Hb with mobility between that of HbA and HbA2 and adjacent to HbA was detected by HPLC. Retention time (RT) was determined as 2.82 min (Figure 1A). Sequencing data of the α2 globin gene for the second case showed the presence of the GCT→CCT mutation in heterozygous form at codon 21, corresponding to the heterozygous Hb Fontainebleau [α21(B2)Ala→Pro;GCT→CCT] (Figure 2A and B). The other abnormal Hb was 18.4% of total Hbs with 1.1% HbA2, and RT time was 4.82 min (Figure 1B). This case was identified as Hb Q-Iran in the α2 gene [α75 (EF4) Asp→His; GAC→CAC] by sequencing (Figure 2C and D). Hematological parameters are also given in Table 2.

Figure 1: High performance liquid chromatography analysis of heterozygous of Hb Fontainebleau (A) and Hb Q-Iran (B).
Figure 1:

High performance liquid chromatography analysis of heterozygous of Hb Fontainebleau (A) and Hb Q-Iran (B).

Figure 2: Patterns of alpha2 and alpha1 sequencing; Heterozygous of Hb Fontainebleau (A) and alpha1 gene sequencing (B). Heterozygous of Hb Q-Iran (C) and alpha1 gene sequencing (D).
Figure 2:

Patterns of alpha2 and alpha1 sequencing; Heterozygous of Hb Fontainebleau (A) and alpha1 gene sequencing (B). Heterozygous of Hb Q-Iran (C) and alpha1 gene sequencing (D).

Table 2:

Hematological data of Hb Fontainebleau and Hb Q-Iran subjects.

ParametersHb FontainebleauHb Q-IranReference range
Age/sex16/F15/F
RBC (1012/L)4.514.84.0–5.20
Hb (g/dL)12.312.812.0–16.0
HCT (%)34.134.936.0–48.0
MCV (fL)75.772.780.0–96.0
MCH (Pg)27.326.728.0–34.0
MCHC (g/d)L36.136.732.0–36.0
RDW (%)16.216.512.0–15.0
HbA2 (%)2.81.12.20–3.50
HbF (%)0.30.1<1.0
Unknown Hb (%)18.018.4
Genotypeα2Cd21 Ala→Pro; GCT→CCTα2Cd75 Asp→His; GAC→CAC

Discussion

Although our country is in the thalassemia belt, there are only a few provinces that determine the frequency and genotypes of α-thal. In particular, there are no studies to determine the prevalence and genotypes of α-thal in the Eastern and Southeastern Anatolia Regions in Turkey. In our country, the incidences of α-thal in Adana and Isparta province, respectively, are 7.5% (n=225) and 17.4% (n=8) [6], [7]. Besides, α-thal mutation screening is performed in a few centers, and many mutations have been identified with different frequency.

In Istanbul, 14 different mutations were found in the largest city, and the most common mutation was reported as –α3.7 with a 23.1% frequency rate (Table 1) [13]. Onay et al. reported 12 different mutations in the α-globin gene cluster and the highest incidence of –α3.7 deletion (52.2%) [14]. Other studies were performed with selected samples who attended clinic and/or hematology had anemia [6], [7], [8], [13], [14]. Although there was no population screening for α-thal to determine prevalence and mutations, this study was conducted with 3571 high school children’s blood samples, and we reported that α-thal prevalence was 1.06% (total 38 students/3571) in Adıyaman Province [9]. The most common mutation in the α-globin genes was the 3.7 single gene deletion, detected in 32 patients with 11.07% frequency (Table 1). While high school students were screened for thalassemia, two α-globin variant was detected in two students.

Hb Fontainebleau results from a G→C substitution (GCT→CCT) at codon 21 of the α-globin gene, changing alanine to proline. The variant was first described in an Italian family, which was identified as a family with hereditary spherocytosis [15], and subsequently described independently as one case in an Iraqi man living in New Zealand [16]. Another case was reported in Cyprus while screening the Greek Cypriot population for thalassemia [17]. The heterozygote individual had normal hematological parameters and the abnormal Hb amounted to 25–29% of the total Hb in six adult cases [15], [16], [17]. The fourth occurrence was a 3-day-old female baby and her mother, who reported with sickle hemoglobin during newborn screening in India. The other two cases in India were reported in the heterozygous in a 35-year-old pregnant woman and a case of heterozygous with iron deficiency anemia [18], [19]. Furthermore, the amount of this variant and HbS combination was reported to be 8.5% of the total Hb in the proband’s mother [20].

The other case, coinheritance of the β-globin chain variant (Hb D-Punjab) with heterozygous Hb Fontainebleau, was reported in an infant by Rodríguez-Capote et al. [21]. Turner et al. reported the first homozygous a case for Hb Fontainebleau; six cases of heterozygote of this variant; four cases with –α3.7/αα; and one case that combined heterozygous with αT Saudiα [22]. The variant was first described in a 37-year old female by Canatan et al. [23]. However, the latest information provides details about the second case of heterozygous Hb Fontainebleau with mild microcytosis in population screening in Adıyaman, Turkey. Furthermore, we report another rare alpha variant, heterozygous Hb Q-Iran.

The case of Hb Q-Iran [α75 (EF4) Asp→His;GAC→CAC] was reported for the first time with two cases in North Central Turkey and Ankara with normal hematology [24]. This variant was also reported as homozygous in one case that originated from Sivas, Central Anatolia in Turkey [25]. The other two cases were a case of acute lymphoblastic leukemia with Hb S and a case of spinal ischemia with α-thal combination [26], [27]. This variant is found sporadically in our country [28]. Individuals carrying Hb Q-Iran are hematologically normal, but in this case had microcytosis and low HbA2 values (Table 2).

The cases of Hb Fontainebleau and Hb Q-Iran occurred in Turkish girls living in the Gölbaşı district of Adıyaman Province and the city center, southeastern Turkey, respectively. Therefore, this case different α-thal deletion or iron deficiency anemia had probably coexisted. As a result, we can conclude that the identification of alpha variants is important for the clinical management of Hb disorder.

Acknowledgements

This study was supported by the Adıyaman University Research Fund SHMYOBAP/ 2014-0001.

References

1. Oron-Karni V, Filon D, Shifrin Y, Fried E, Pogrebijsky G, Oppenheim A, et al. Diversity of alpha-globin mutations and clinical presentation of alpha-thalassemia in Israel. Am J Hematol 2000;65:196–203.10.1002/1096-8652(200011)65:3<196::AID-AJH4>3.0.CO;2-8Search in Google Scholar

2. Karamzade A, Mirzapour H, Hoseinzade M, Asadi S, Gholamrezapour T, Tavakoli P, et al. α-globin gene mutations in Isfahan Province, Iran. Hemoglobin 2014;38:161–4.10.3109/03630269.2014.893531Search in Google Scholar

3. Origa R, Paglietti ME, Sollaino MC, Desogus MF, Barella S, Loi D, et al. Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia. Blood Cells Mol Dis 2014;52:46–9.10.1016/j.bcmd.2013.06.004Search in Google Scholar

4. Chow A, Ghassemifar R, Finlayson J. Alpha thalassaemia due to non-deletional mutations on the -3.7 alpha globin fusion gene: laboratory diagnosis and clinical importance. Pathology 2013;45:591–4.10.1097/PAT.0b013e32836526d7Search in Google Scholar

5. Oner C, Gürgey A, Oner R, Balkan H, Gümrük F, Baysal E, et al. The molecular basis of Hb H disease in Turkey. Hemoglobin 1997;21:41–51.10.3109/03630269708997509Search in Google Scholar

6. Guvenc B, Yildiz SM, Tekinturhan F, Dincer S, Akyuzluer I, Okten S, et al. Molecular characterization of alpha-thalassemia in Adana, Turkey: a Single Center Study. Acta Haematol 2010;123:197–200.10.1159/000302203Search in Google Scholar

7. Gulen H, Hanimeli O, Karaca O, Taneli F. α-Thalassemia frequency and mutations in children with hypochromic microcytic anemias and relation with β-thalassemia, iron deficiency anemia. Pediatr Hematol Oncol 2012;29:241–6.10.3109/08880018.2012.661831Search in Google Scholar

8. Celik MM, Gunesacar R, Oktay G, Duran GG, Kaya H. Spectrum of α-thalassemia mutations including first observation of – -(FIL) deletion in Hatay Province, Turkey. Blood Cells Mol Dis 2013;51:27–30.10.1016/j.bcmd.2013.01.012Search in Google Scholar

9. Genc A, Tastemir Korkmaz D, Urhan Kucuk M, Rencuzogullari E, Atakur S, Bayram S, et al. Prevalence of beta-thalassemia trait and abnormal hemoglobins in the province of Adıyaman, Turkey. Pediatr Hematol Oncol 2012;29:620–3.10.3109/08880018.2012.713085Search in Google Scholar

10. Lacerra G, Musollino G, Di Noce F, Prezioso R, Carestia C. Genotyping for known Mediterranean alpha-thalassemia point mutations using a multiplex amplification refractory mutation system. Haematologica 2007;92:254–5.10.3324/haematol.10736Search in Google Scholar

11. Liu YT, Old JM, Miles K, Fisher CA, Wheatherall DJ, Clegg JB. Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplications by multiplex polymerase chain reactions. Br J Haematol 2000;108:295–9.10.1046/j.1365-2141.2000.01870.xSearch in Google Scholar PubMed

12. Ayala S, Colomer D, Pujades A, Aymerich M, Corrons JL. Haemoglobin Lleida: a new alpha 2-globin variant (12 bp deletion) with mild thalassaemic phenotype. Br J Haematol 1996;94;639–44.10.1046/j.1365-2141.1996.d01-1840.xSearch in Google Scholar PubMed

13. Karakaş Z, Koç B, Temurhan S, Elgün T, Karaman S, Asker G, et al. Evaluation of alpha-thalassemia mutations in cases with hypochromic microcytic anemia: The İstanbul perspective. Turk J Hematol, 2015;32:344–350.10.4274/tjh.2014.0204Search in Google Scholar PubMed PubMed Central

14. Onay H, Aykut A, Karaca E, Durmaz A, Solmaz AE, Çoğulu Ö, et al. Molecular spectrum of α-globin gene mutations in the Aegean region of Turkey: first observation of three α-globin gene mutations in the Turkish population. Int J Hematol 2015;102:1–6.10.1007/s12185-015-1796-ySearch in Google Scholar PubMed

15. Wajcman H, Blouquit Y, Gombaud-Saintonge G, Riou J, Galacteros F. Hb Fontainebleau [alpha 21(B2)Ala----pro], a new silent mutant hemoglobin. Hemoglobin 1989;13:421–8.10.3109/03630268908998081Search in Google Scholar PubMed

16. Brennan SO, Chan T, Ryken S, Ruskova A. A second case of Hb Fontainebleau [alpha21(B2)Ala–>Pro] in an individual with microcytosis. Hemoglobin 2009;33:258–61.10.1080/03630260903061135Search in Google Scholar PubMed

17. Kyrri AR, Felekis X, Kalogerou E, Wild BJ, Kythreotis L, Phylactides M, et al. Hemoglobin variants in Cyprus. Hemoglobin 2009;33:81–94.10.1080/03630260902813502Search in Google Scholar PubMed

18. Purohit A, Aggarwal M, Colah RB, Nadkarni AH, Pati HP. A case of iron deficiency anemia with co-existing Hb Fontainebleau. Mediterr J Hematol Infect Dis 2014;6:e2014051.10.4084/mjhid.2014.051Search in Google Scholar

19. Mashon RS, Nair S, Sawant P, Colah RB, Ghosh K, Das S. Hemoglobin Fontainebleau [a21(B2)Ala–>Pro]: The second report from India. Indian J Hum Genet 2013;19:352–4.10.4103/0971-6866.120822Search in Google Scholar PubMed PubMed Central

20. Upadhye DS, Jain D, Nair SB, Nadkarni AH, Ghosh K, Colah RB. First case of Hb Fontainebleau with sickle haemoglobin and other non-deletional α gene variants identified in neonates during newborn screening for sickle cell disorders. J Clin Pathol 2012;65:654–9.10.1136/jclinpath-2011-200642Search in Google Scholar PubMed

21. Rodríguez-Capote K, Estey MP, Barakauskas V, Bordeleau P, Christensen CL, Zuberbuhler P, et al. A novel double heterozygous Hb Fontainebleau/HbD Punjab hemoglobinopathy. Clin Biochem 2015;48:904–7.10.1016/j.clinbiochem.2015.05.020Search in Google Scholar PubMed

22. Turner A, Sasse J, Varadi A. Hb Fontainebleau (HBA2: c.64G>C) in the United Arab Emirates. Hemoglobin 2014;38:216–20.10.3109/03630269.2014.912221Search in Google Scholar PubMed

23. Canatan D, Bilgen T, Çiftçi V, Yazıcı G, Delibaş S, Keser İ. First observation of hemoglobin G-Waimanalo and hemoglobin Fontainebleau cases in the Turkish Population. Turk J Hematol 2016;33:71–2.10.4274/tjh.2015.0299Search in Google Scholar PubMed PubMed Central

24. Aksoy M, Gurgey A, Altay C, Kilinc Y, Carstairs KC, Kutlar A, et al. Some notes about Hb Q-India and Hb Q-Iran. Hemoglobin 1986;10:215–9.10.3109/03630268609046447Search in Google Scholar PubMed

25. Ozdag H, Yildiz I, Akar N. First observation of homozygote Hb Q-Iran (alpha 75 (EF4) Asp-His). Turk J Hematol 2008;25:48–50.Search in Google Scholar

26. Gürgey A, Ozsoylu S, Hiçsönmez G, Irken G, Altay C. Acute lymphoblastic leukemia in a child with hemoglobins S and Q-Iran. Turk J Pediatr 1990;32:39–41.Search in Google Scholar

27. Zur B, Hildesheim A, Ludwig M, Stoffel-Wagner B. A first report on Hb Q-Iran in association with alpha-thalassemia in a case of spinal ischemia. Clin Lab 2011;57:221–4.Search in Google Scholar

28. Altay C. Abnormal hemoglobins in Turkey. Turk J Hematol 2002;19:63–74.Search in Google Scholar

Received: 2016-03-16
Accepted: 2016-04-25
Published Online: 2016-10-18
Published in Print: 2016-12-01

©2016 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 28.11.2022 from frontend.live.degruyter.dgbricks.com/document/doi/10.1515/tjb-2016-0149/html
Scroll Up Arrow